1. Home
  2. OTLK vs NTWK Comparison

OTLK vs NTWK Comparison

Compare OTLK & NTWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OTLK
  • NTWK
  • Stock Information
  • Founded
  • OTLK 2010
  • NTWK 1997
  • Country
  • OTLK United States
  • NTWK United States
  • Employees
  • OTLK N/A
  • NTWK N/A
  • Industry
  • OTLK Biotechnology: Biological Products (No Diagnostic Substances)
  • NTWK Computer Software: Prepackaged Software
  • Sector
  • OTLK Health Care
  • NTWK Technology
  • Exchange
  • OTLK Nasdaq
  • NTWK Nasdaq
  • Market Cap
  • OTLK 42.8M
  • NTWK 34.9M
  • IPO Year
  • OTLK 2016
  • NTWK 1998
  • Fundamental
  • Price
  • OTLK $1.69
  • NTWK $3.00
  • Analyst Decision
  • OTLK Buy
  • NTWK
  • Analyst Count
  • OTLK 5
  • NTWK 0
  • Target Price
  • OTLK $5.25
  • NTWK N/A
  • AVG Volume (30 Days)
  • OTLK 4.5M
  • NTWK 99.8K
  • Earning Date
  • OTLK 12-26-2025
  • NTWK 11-12-2025
  • Dividend Yield
  • OTLK N/A
  • NTWK N/A
  • EPS Growth
  • OTLK N/A
  • NTWK N/A
  • EPS
  • OTLK N/A
  • NTWK 0.04
  • Revenue
  • OTLK $1,505,322.00
  • NTWK $66,501,654.00
  • Revenue This Year
  • OTLK N/A
  • NTWK N/A
  • Revenue Next Year
  • OTLK $342.80
  • NTWK N/A
  • P/E Ratio
  • OTLK N/A
  • NTWK $74.42
  • Revenue Growth
  • OTLK N/A
  • NTWK 7.70
  • 52 Week Low
  • OTLK $0.79
  • NTWK $2.14
  • 52 Week High
  • OTLK $5.18
  • NTWK $5.75
  • Technical
  • Relative Strength Index (RSI)
  • OTLK 59.10
  • NTWK 31.96
  • Support Level
  • OTLK $1.76
  • NTWK $2.80
  • Resistance Level
  • OTLK $2.02
  • NTWK $3.16
  • Average True Range (ATR)
  • OTLK 0.20
  • NTWK 0.21
  • MACD
  • OTLK 0.04
  • NTWK -0.03
  • Stochastic Oscillator
  • OTLK 59.38
  • NTWK 19.33

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

About NTWK NetSol Technologies Inc. Common Stock

NETSOL Technologies Inc is an information technology and enterprise software solutions provider to original equipment manufacturers (OEMs), dealerships, and financial institutions to sell, finance, and lease assets. The firm's products include Transcend Retail, Transcend Finance, Transcend Marketplace, Transcend Consultancy, and Transcend AI Labs, catering to its customers in the different stages of how assets are sold, financed, and leased. Its primary sources of revenue are licensing, subscriptions, modification, enhancement, and support of its suite of financial applications offered to businesses in the finance and leasing space, as well as automotive digital retail. The company has three reportable segments: Asia-Pacific, its key revenue-generating market, North America, and Europe.

Share on Social Networks: